The revenue increase was primarily due to $34.2 million of incremental revenue provided by our Health Management segment principally as a result of incremental revenues from recently acquired
Novo Nordisk has provided the data of liraglutide study. It showed that once-daily liraglutide (an investigational treatment for type 2 diabetes) leads to significant and sustained reductions in
Novartis’ Ilaris (canakinumab) has received a recommendation for approval in the EU. The drug is to treat patients with a life-long and potentially fatal auto-inflammatory disease – cryopyrin-associated
Merck & Co. has proposed a settlement, subject to Court approval, to resolve litigation challenging the planned merger between Merck and Schering-Plough and seeking other forms of relief.
Compass Pharma has completed a capital investment project to upgrade its production capabilities to include ISO Class 8 (ISO 14644) specifications, so as to provide packaging services for
SeattleGenetics has initiated a phase II clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), for the re-treatment of patients with Hodgkin lymphoma and systemic anaplastic large
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA), has issued a positive opinion for the marketing authorization of Regeneron’s rilonacept in
Compass Pharma Services has upgraded its production facility to include ISO Class 8 (ISO 14644) specifications in order to provide packaging services for certain high-potency pharmaceutical products. The
In order to provide contract pharmaceutical packaging services for certain high-potency pharmaceutical products, Compass Pharma Services has announced the completion of a capital investment project to upgrade its
CytRx’s drug candidate, tamibarotene has received official notification from the Committee for Orphan Medicinal Products (COMP) of the EMEA. Reportedly, a positive opinion was made regarding the application
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.